Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs

Vaccine ◽  
2007 ◽  
Vol 25 (7) ◽  
pp. 1334-1341 ◽  
Author(s):  
Shinya Fukumoto ◽  
Yoh Tamaki ◽  
Masashi Okamura ◽  
Hiroshi Bannai ◽  
Natsuko Yokoyama ◽  
...  
2013 ◽  
Vol 58 (4) ◽  
Author(s):  
Shinuo Cao ◽  
Ahmed Mousa ◽  
Gabriel Aboge ◽  
Ketsarin Kamyingkird ◽  
Mo Zhou ◽  
...  

AbstractA heterologous prime-boost vaccination regime with DNA and recombinant vaccinia virus (rvv) vectors expressing relevant antigens has been shown to induce effective immune responses against several infectious pathogens. In this study, we describe the effectiveness of the prime-boost strategy by immunizing dogs with a recombinant plasmid followed by vaccinia virus, both of which expressed the glutamic acid-rich protein (BgGARP) of Babesia gibsoni. The dogs immunized with the prime-boost regime developed a significantly high level of specific antibodies against BgGARP when compared with the control groups. The antibody level was strongly increased after a booster immunization with a recombinant vaccinia virus. Two weeks after the booster immunization with a recombinant vaccinia virus expressing BgGARP, the dogs were challenged with B. gibsoni parasite. The dogs immunized with the prime-boost regime showed partial protection, manifested as a significantly low level of parasitemia. These results indicated that this type of DNA/rvv prime-boost immunization approach may have use against B. gibsoni infection in dogs.


1997 ◽  
Vol 59 (3-4) ◽  
pp. 293-309 ◽  
Author(s):  
Zelia I.P. Lobato ◽  
Barbara E.H. Coupar ◽  
Christian P. Gray ◽  
Ross Lunt ◽  
Marion E. Andrew

1998 ◽  
Vol 72 (12) ◽  
pp. 9567-9574 ◽  
Author(s):  
Joseph E. Blaney ◽  
Eri Nobusawa ◽  
Michael A. Brehm ◽  
Robert H. Bonneau ◽  
Lawrence M. Mylin ◽  
...  

ABSTRACT We have evaluated the potential of conferring protective immunity to herpes simplex virus type 2 (HSV-2) by selectively inducing an HSV-specific CD8+ cytotoxic T-lymphocyte (CTL) response directed against a single major histocompatibility complex class I-restricted CTL recognition epitope. We generated a recombinant vaccinia virus (rVV-ES-gB498-505) which expresses the H-2Kb-restricted, HSV-1/2-cross-reactive CTL recognition epitope, HSV glycoprotein B residues 498 to 505 (SSIEFARL) (gB498-505), fused to the adenovirus type 5 E3/19K endoplasmic reticulum insertion sequence (ES). Mucosal immunization of C57BL/6 mice with this recombinant vaccinia virus induced both a primary CTL response in the draining lymph nodes and a splenic memory CTL response directed against HSV gB498-505. To determine the ability of the gB498-505-specific memory CTL response to provide protection from HSV infection, immunized mice were challenged with a lethal dose of HSV-2 strain 186 by the intranasal (i.n.) route. Development of the gB498-505-specific CTL response conferred resistance in 60 to 75% of mice challenged with a lethal dose of HSV-2 and significantly reduced the levels of infectious virus in the brains and trigeminal ganglia of challenged mice. Finally, i.n. immunization of C57BL/6 mice with either a recombinant influenza virus or a recombinant vaccinia virus expressing HSV gB498-505 without the ES was also demonstrated to induce an HSV-specific CTL response and provide protection from HSV infection. This finding confirms that the induction of an HSV-specific CTL response directed against a single epitope is sufficient for conferring protective immunity to HSV. Our findings support the role of CD8+ T cells in the control of HSV infection of the central nervous system and suggest the potential importance of eliciting HSV-specific mucosal CD8+ CTL in HSV vaccine design.


2009 ◽  
Vol 38 (8) ◽  
pp. 762-779 ◽  
Author(s):  
Duanthanorm Promkhatkaew ◽  
Nadthanan Pinyosukhee ◽  
Wilai Thongdeejaroen ◽  
Jantima Teeka ◽  
Preeda Wutthinantiwong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document